<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02719808</url>
  </required_header>
  <id_info>
    <org_study_id>XJTU1AHCR2014-018</org_study_id>
    <nct_id>NCT02719808</nct_id>
  </id_info>
  <brief_title>Study of Antiretroviral Therapy to Prevent HBV Intrauterine Infection</brief_title>
  <official_title>A Cohort Study of Tenofovir on Blocking HBV Intrauterine Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>First Affiliated Hospital Xi'an Jiaotong University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>First Affiliated Hospital Xi'an Jiaotong University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      500 pregnant patients with HBeAg-positive and HBV-DNA&gt; 106copies /ml who will do their
      pregnant check in the First Affiliated Hospital of Xi'an Jiaotong University will be enrolled
      into the study. There will be five groups to be observed. Four groups are taking tenofovir to
      prevent intrauterine infection during pregnancy. One group is not taking any anti-HBV virus
      treatments.The clinical value and effectiveness of tenofovir on blocking HBV intrauterine
      infection will be evaluated; The HBV-DNA infection status of placenta tissue will be checked
      by quantitative Polymerase Chain Reaction (PCR) to assess the changes of HBV-DNA of placenta
      after treating with tenofovir and explore the mechanism of tenofovir blocking HBV
      intrauterine infection. The safety of Tenofovir will be assessed as well.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2015</start_date>
  <completion_date type="Anticipated">February 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>deoxyribonucleic acid of Hepatitis B Virus (HBV-DNA) in serum</measure>
    <time_frame>up to 1 year</time_frame>
    <description>Check HBV-DNA in serum by ELISA in pregnant women. The measure unit is copies/mL</description>
  </primary_outcome>
  <primary_outcome>
    <measure>deoxyribonucleic acid of Hepatitis B Virus (HBV-DNA) in serum</measure>
    <time_frame>up to 1 year</time_frame>
    <description>Check HBV-DNA in serum by quantitative PCR in pregnant women. The measure unit is copies/mL</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>the concentration of Interleukin 2 (IL-2)</measure>
    <time_frame>up to 1 year</time_frame>
    <description>the concentration of Interleukin 2 (IL-2)in serum of pregnant women, U/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>interferon-γ (IFN-γ)</measure>
    <time_frame>up to 1 year</time_frame>
    <description>the concentration of interferon-γ (IFN-γ) in serum of pregnant women,U/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interleukin 4 (IL-4)</measure>
    <time_frame>up to 1 year</time_frame>
    <description>the concentration of Interleukin 4 (IL-4)in serum of pregnant women, U/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interleukin 6 (IL-6)</measure>
    <time_frame>up to 1 year</time_frame>
    <description>the concentration of Interleukin 6 (IL-6)in serum of pregnant women,U/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T cell ratio</measure>
    <time_frame>up to 1 year</time_frame>
    <description>T cell ratio in serum is measured by follow cytometry in pregnant women</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HBV-DNA of babies</measure>
    <time_frame>when the baby is 7-month-old</time_frame>
    <description>Check HBV-DNA by ELISA and quantitative PCR. The measure unit is copies/mL. All babies who used tenofovir will be tested when he is 7-month-old, in order to make sure whether they have infection during pregnant period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hepatitis B e-antigen (HBeAg)</measure>
    <time_frame>up to 1 year</time_frame>
    <description>check HBeAg in serum of pregnant women.the measure unit is PEIU/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HBV-DNA in placenta tissue</measure>
    <time_frame>the date of delivery</time_frame>
    <description>Check HBV-DNA of placenta tissue by quantitative PCR. The measure unit is copies/mL.</description>
  </secondary_outcome>
  <number_of_groups>5</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Hepatitis B, Chronic</condition>
  <arm_group>
    <arm_group_label>Tenofovir1</arm_group_label>
    <description>100 patients receive tenofovir （300mg/d）from (28±2） weeks of pregnancy to one week after delivery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tenofovir2</arm_group_label>
    <description>100 patients receive tenofovir （300mg/d）from (28±2） weeks of pregnancy to one month after delivery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tenofovir3</arm_group_label>
    <description>100 patients receive tenofovir （300mg/d）from （20±2）weeks of pregnancy to one week after delivery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tenofovir4</arm_group_label>
    <description>100 patients receive tenofovir （300mg/d）from （20±2）weeks of pregnancy to one month after delivery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group without any treatment</arm_group_label>
    <description>100 patients don't receive any blockade therapies</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenofovir1</intervention_name>
    <description>receive tenofovir （300mg/d）from （28±2）weeks of pregnancy to one month after delivery, it is the observational exposure.</description>
    <arm_group_label>Tenofovir1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenofovir2</intervention_name>
    <description>receive tenofovir （300mg/d）from（28±2）weeks of pregnancy to one month after delivery, it is the observational exposure.</description>
    <arm_group_label>Tenofovir2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenofovir3</intervention_name>
    <description>receive tenofovir （300mg/d）from （20±2）weeks of pregnancy to one month after delivery, it is the observational exposure.</description>
    <arm_group_label>Tenofovir3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenofovir4</intervention_name>
    <description>receive tenofovir （300mg/d）from （20±2）weeks of pregnancy to one week after delivery, it is the observational exposure.</description>
    <arm_group_label>Tenofovir4</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood, placenta tissue of HBeAg-positive pregnant women
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        pregnant women with HBeAg-positive and HBV-DNA&gt;106copies/ml from the out-patient department
        of First Affiliated Hospital of Xi'an Jiaotong University
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  pregnancy patients with HBeAg-positive and HBV-DNA&gt; 106copies /ml

        Exclusion Criteria:

          -  pregnancy patients with HBeAg-negative or HBV-DNA＜106copies /ml
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guiqin Bai, M.D.;Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>First Affiliated Hospital Xi'an Jiaotong University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Guiqin Bai, M.D.;Ph.D.</last_name>
    <phone>86-18991232517</phone>
    <email>baigq@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>First Affiliated Hospital of Xi'an Jiaotong University</name>
      <address>
        <city>Xi'an</city>
        <state>Shaanxi</state>
        <zip>710061</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guiqin Bai, M.D.;Ph.D.</last_name>
      <phone>86-18991232517</phone>
      <email>baigq@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 6, 2016</study_first_submitted>
  <study_first_submitted_qc>March 24, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 25, 2016</study_first_posted>
  <last_update_submitted>September 23, 2016</last_update_submitted>
  <last_update_submitted_qc>September 23, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 26, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Vertical infection transmission</keyword>
  <keyword>Tenofovir</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

